Iovance Biotherapeutics Announces U.S. Food and Drug Administration Acceptance of the Biologics…
Priority Review Granted withPrescription Drug User Fee Act (PDUFA) Action Date of November 25, 2023 First Potential Approval of an Individualized, One-Time Cell Therapy for Patients with Advanced Melanoma SAN CARLOS, Calif., May…